The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Thrombosis Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.thromres.2014.11.009PMID 25527332PMCID PMC4272760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

  2014cited by this paper
• Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.

  2014cited by this paper
• Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.

  2013cited by this paper
• Biomolecular markers of cancer-associated thromboembolism.

  2013cited by this paper
• Biomarkers for prediction of venous thromboembolism in cancer.

  2013cited by this paper
• Ponatinib pulled off market over safety issues.

  2013cited by this paper
• p21 Activated Kinase Signaling Coordinates Glycoprotein Receptor VI–Mediated Platelet Aggregation, Lamellipodia Formation, and Aggregate Stability Under Shear

  2013cited by this paper
• Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1.

  2013cited by this paper
• Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

  2013cited by this paper
• Platelet shape change and spreading.

  2012cited by this paper
• Distinct and overlapping functional roles of Src family kinases in mouse platelets

  2012cited by this paper
• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

  2012influential reference
• The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

  2012cited by this paper
• Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation.

  2011cited by this paper
• Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells

  2011cited by this paper
• Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

  2011cited by this paper
• S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.

  2011cited by this paper
• Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.

  2011cited by this paper
• Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

  2010cited by this paper
• Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009influential reference
• Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion.

  2009cited by this paper
• The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

  2009cited by this paper
• AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

  2006cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• GPVI and integrin αIIbβ3 signaling in platelets

  2005cited by this paper
• Imatinib as a paradigm of targeted therapies.

  2004influential reference
• Exposure of platelet membrane phosphatidylserine regulates blood coagulation.

  2003cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates

  2000cited by this paper
• Crystal structures of c-Src reveal features of its autoinhibitory mechanism.

  1999cited by this paper
• LAT Is Required for Tyrosine Phosphorylation of Phospholipase Cγ2 and Platelet Activation by the Collagen Receptor GPVI

  1999cited by this paper
• A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

  1998cited by this paper
• Regulation of Btk function by a major autophosphorylation site within the SH3 domain.

  1996cited by this paper

• Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis

  2025cites this paper
• KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

  2025cites this paper
• Safe platelet count for lumbar puncture: are we being overcautious?

  2025cites this paper
• 40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies

  2025cites this paper
• A Review on Medicinal Approaches of Novel Imatinib Derivatives.

  2025cites this paper
• Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.

  2024cites this paper
• Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis

  2024cites this paper
• Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function.

  2024cites this paper
• Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish.

  2024cites this paper
• Imatinib‑ and ponatinib‑mediated cardiotoxicity in zebrafish embryos and H9c2 cardiomyoblasts

  2024cites this paper
• Superficial Femoral Artery Atherosclerosis Masquerading as Sciatica: Diagnosis and Conservative Management – A Case Report

  2024cites this paper
• Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology

  2023cites this paper
• Ponatinib: An update on its drug targets, therapeutic potential and safety.

  2023cites this paper
• Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database

  2023cites this paper
• Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo

  2022cites this paper
• Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan

  2022cites this paper
• Ponatinib-Induced Cerebrovascular Accident (CVA)

  2022influential citation
• Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity

  2022cites this paper
• Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology.

  2022cites this paper
• [French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].

  2022cites this paper
• Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.

  2022cites this paper
• Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

  2022cites this paper
• Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function

  2021cites this paper
• Impact of Tyrosine Kinase Inhibitors Applied for First-Line Chronic Myeloid Leukemia Treatment on Platelet Function in Whole Blood of Healthy Volunteers In Vitro

  2021cites this paper
• Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

  2021cites this paper
• Ponatinib Exerts an Inhibitory Effect on Collagen-induced Platelet Aggregation and Generation of Coated-Platelets

  2021cites this paper
• Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells.

  2021cites this paper
• Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis

  2021cites this paper
• Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation.

  2020cites this paper
• Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy.

  2020cites this paper
• Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia

  2020cites this paper
• Vascular toxic effects of cancer therapies

  2020cites this paper
• Advances in Supportive Care for Acute Lymphoblastic Leukemia

  2020cites this paper
• Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

  2020cites this paper
• Platelet function in patients with chronic myeloid leukemia treated with asciminib

  2020cites this paper
• A Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.

  2020cites this paper
• Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis

  2020influential citation
• How to manage CML patients with comorbidities?

  2020cites this paper
• Complex cytogenetic abnormalities in chronic myeloid leukemia resulting in early progression to blast crisis: a case report

  2020cites this paper
• How to manage CML patients with comorbidities.

  2020cites this paper
• ATVB IN FOCUS: Cardiovascular Effects of Anticancer Treatments/Agents

  2020cites this paper
• Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

  2019cites this paper
• Potential Successes and Challenges of Targeted Cancer Therapies.

  2019cites this paper
• Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?

  2019cites this paper
• Methods for measurement of platelet function in the assessment of nonclinical drug safety and implications for translatability

  2019cites this paper
• Chitosan biopolymer‐derived self‐powered triboelectric sensor with optimized performance through molecular surface engineering and data‐driven learning

  2019cites this paper
• Hematological Malignancies and Arterial Thromboembolism

  2019cites this paper
• Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

  2019cites this paper
• Venous thromboembolism incidence in hematologic malignancies.

  2019cites this paper
• Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.

  2019cites this paper
• Ponatinib treatment promotes arterial thrombosis and hyperactive platelets.

  2019cites this paper
• BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

  2018cites this paper
• Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase

  2018cites this paper
• Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

  2018influential citation
• Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

  2018cites this paper
• Differential effects of tyrosine kinase inhibitors in haemostasis, thrombosis and inflammation

  2018influential citation
• Cardiovascular Damage Induced by Anti-BCR-ABL TKIs

  2018cites this paper
• Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis

  2018cites this paper
• Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

  2018cites this paper
• Acquired platelet antagonism: off‐target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors

  2018cites this paper
• Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

  2018cites this paper
• The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

  2018cites this paper
• Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

  2017cites this paper
• Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion

  2017cites this paper
• Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia

  2017cites this paper
• Thrombosis in adult patients with acute leukemia

  2017cites this paper
• Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets.

  2016cites this paper
• Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

  2016cites this paper
• A Novel Prioritization Method in Identifying Recurrent Venous Thromboembolism-Related Genes

  2016cites this paper
• Molecular mechanisms for vascular complications of targeted cancer therapies.

  2016cites this paper
• Oncocardiology-Past, Present, and Future: A Review.

  2016cites this paper
• Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

  2015cites this paper
• Platelet function in malignant hematological disorders

  2015cites this paper
• Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

  2015cites this paper
• Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

  2015cites this paper
• Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.

  2015cites this paper
• ATVB IN FOCUS: Cardio-Oncology and Vascular Diseases

  year unknowncites this paper